Lunit Inc. · KRX:328130

Lunit — Investor Presentation (November 2026)

27 slides from Lunit's investor presentation, November 2026

  1. Slide 1: Conquer Cancer through AI

    Conquer Cancer through Al © Lunit

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation has been prepared by Lunit Inc. solely for information purposes. The information contained in this presentation has not been independently verified. No representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accurac

  3. Slide 3: Lunit: Setting a New Standard for Medical AI in Cancer

    Company Overview · Business Structure Lunit : Setting a New Standard for Medical AI in Cancer Screening: recurring revenue via SaaS, B2G & reimbursement · Oncology: -growth high engine via pharma (ADC·IO) partnerships First -Gen Medical AI Company Consol. revenue (KRW 100M) 1H 2H Full Year 2013 2024

  4. Slide 4: Growth Continues as Losses and Financial Burden Decline

    Investment Highlights Growth Continues as Losses and Financial Burden Decline 01 Cancer Screening 02 Oncology 03 Profitability 04 Capital Structure Revenue 4x Since Partnering with 15 EBITDA Loss 81% of Existing Acquisition of Top 20 Pharma Decrease 77% CBs Resolved KRW 18.3B (2023) → 72.8B 5 pharma

  5. Slide 5: Amid Continued Peer Losses, Lunit Improves Margins Fastest

    Profitability · Global Peer Comparison Amid Continued Peer Losses, Lunit Improves Margins Fastest Global medical AI companies with 1.5 –23x Lunit’s revenue all post negative EBITDA — Lunit improved its EBITDA margin by 84%p in two years Global peers: all loss-making despite scale Annual Revenue · EB

  6. Slide 6: Cancer Screening

    SECTION LABEL Cancer Screening Strictly confidential. Internal use only.

  7. Slide 7: Connecting the Entire Screening Journey in One Product Suite

    Cancer Screening Product Lineup Connecting the Entire Screening Journey in One Product Suite Pre-scan Scan Reading Diagnostic Support Follow-up Risk Pathways Live Scorecard Lunit INSIGHT Analytics LIL | Cancer risk assessment LIL | Real -time image QC LIL | Breast density assessment Lunit | MMG·DBT·

  8. Slide 8: Outperforming Competitors — AI CAD

    Cancer Screening · AI CAD Performance Outperforming Competitors — AI CAD Higher reading accuracy than specialists, proven by leading studies and publications Validated at leading institutions worldwide Top 3 mammography AI compared Salim, et al. JAMA Oncol. 2020 Aug 27. Karolinska IF 24.7991) Instit

  9. Slide 9: Cancer Screening by Region

    Cancer Screening · Regional Strategy Lunit Japan Cancer Screening by Region Lunit International Lunit HQ Expanding globally with optimized, tailored strategies for each region Lunit Europe Holdings Cancer Screening Revenue Trend 49,964 72,755 4,085 EMEA, 6% North America EMEA 28,651 Japan/Korea/APAC

  10. Slide 10: US Business Strategy

    Cancer Screening · Regional Strategy US Business Strategy Major healthcare institutions secured across the US 100+ US staff incl. direct sales team International Becky Weber ~20 100+ EVP Sales Sales US Team Dan Byrne Travis Larrison Nicki Bryan Senior Sales Senior Sales Senior Sales Director Directo

  11. Slide 11: Ex-US Business Strategy

    Cancer Screening · Regional Strategy Ex-US Business Strategy Global partner channels, Korea·Japan reimbursement, and B2G in 15 countries drive growth outside the US Partnerships Reimbursement B2G Roadmap First case Japan In Japan 2027 H1 2027 H2 2028 H1 INSIGHT Coverage Coverage X-ray CXR nHTA → Rev

  12. Slide 12: From Reading to Risk Prediction — Images Based Risk AI

    Cancer Screening · INSIGHT Risk (IBR) · MMG From Reading to Risk Prediction — Images Based Risk AI Developed & validated by WashU School of Medicine researchers — clinical accuracy proven vs. standard risk models Mammogram → INSIGHT Risk → 5-year breast cancer → Risk-based + Age AI Analysis absolute

  13. Slide 13: Innovating with Future-Oriented Technology

    Cancer Screening · Future Strategy Innovating with Future -Oriented Technology AI-only reading Beyond cancer risk prediction to autonomous AI 01 Now 02 Risk Assessment 03 Foundation Model 04 Autonomous AI AI-CAD AI-Based Risk Prediction AI Customization Autonomous AI in Cancer Screening ▪ AI reading

  14. Slide 14: Oncology

    SECTION LABEL f rH i Le Oncology @ Lunit

  15. Slide 15: 50%+ of New Cancer Drugs Are Biomarker-Based

    Personalized Cancer Therapy · Biomarkers 50%+ of New Cancer Drugs Are Biomarker-Based Biomarkers enable personalized care Conventional: one drug for all patients Diagnosis & Treatment Patient $42B Without Biomarkers 1 Cancer Biomarker Market · 2029E Response Rate Survival Biomarker Test X ~20% 6 mo

  16. Slide 16: Lunit SCOPE IO: AI-Powered Biomarker for Immunotherapy

    Lunit SCOPE IO Lunit SCOPE uIHC Lunit SCOPE IO · Immunotherapy Biomarker Lunit SCOPE IO:AI-Powered Biomaker for Immunotherapy 1 Drug Immunotherapy 2 Biomarker Lunit SCOPE IO 3 Effect Responder selection AI biomarker based on tumor microenvironment analysis AI Analysis Result Immunotherapy 3rd-gen ca

  17. Slide 17: SCOPE IO+ Patients: Increase Immunotherapy Response 2–3x

    Lunit SCOPE IO Lunit SCOPE uIHC Lunit SCOPE IO ·Research Results SCOPE IO+ Patients: Increase Immunotherapy Response 2–3x Monotherapy Phase 1 · Multiple cancer · Anti-PD-1 inhibitor Lung cancer IO response prediction accuracy AUROC Pharma drug: Anti -PD-1 Biomarker: Lunit SCOPE IO PD-L1 Lunit SCOPE

  18. Slide 18: Summit × Lunit: AI Biomarker for Ivonescimab

    Lunit SCOPE IO Lunit SCOPE uIHC Lunit SCOPE IO · Biopharma Partnership Summit ×Lunit: AI Biomarker for Ivonescimab 1 Partner 2 Collaboration Research agreement 3 Impact Why it matters AI TME analysis for ivonescimab Ivonescimab SMT112 · Investigational Announced Oct 23, 2026 · Summit ×Lunit Strategi

  19. Slide 19: Lunit SCOPE uIHC: AI-Powered Quantification of ADC Target

    Lunit SCOPE IO Lunit SCOPE uIHC Lunit SCOPE uIHC · ADC Biomarker Lunit SCOPE uIHC: AI-Powered Quantification of ADC Target 1 Drug ADC 2 Biomarker Lunit SCOPE uIHC 3 Effect Quantitative target analysis AI biomarker based on protein expression quantification ADC Therapy Mechanism Antibody-Drug Conjuga

  20. Slide 20: AI Identifies Patients Missed by Visual Assessment

    Lunit SCOPE IO Lunit SCOPE uIHC AI biomarker journey · Lung cancer TROP2 ADC · Dato-DXd (AstraZeneca·Daiichi Sankyo) AI Identifies Patients Missed by Visual Assessment ① Limit Human reading 2023–2024 ② Shift AI quantitative analysis 2024–2025 ③ Proof AI-based Ph3 2023 · JCO (Phase 1) AZ | Dato-DXd 2

  21. Slide 21: Business Model

    Lunit SCOPE Business Model Business Model Sold with pharma drugs; revenue from pre -treatment eligibility tests Drug price $$$$ Payer STEP 3 Drug Clinical STEP 1 STEP 2 Hospital Drug Patient Development Process SCOPE Test If Positive prescribed Cancer Drug Trial Pharma Lunit SCOPE selects patients S

  22. Slide 22: Big Pharma Partnerships in AI Biomarkers

    Oncology · Global Pharma Partnerships Big Pharma Partnerships in AI Biomarkers Collaboration Summary Collaboration Summary Collaboration Summary ✓ Supporting AstraZeneca’s oncology R&D and ✓ Jointly exploring AI-based ✓ Analyzing and validating a treatment -response pathology workflows through AI-ba

  23. Slide 23: From Pharma Research to Companion Diagnostics (CDx)

    Oncology · Commercialization Roadmap From Pharma Research to Companion Diagnostics (CDx) Step 0 Step 1 Step 2 Step 3 Step 4 Step 5 Pre-engage Engagement RUO Contract Clinical / CDx CDx Approval CDx Revenue FDA Approval SCOPE Test If Positive Cancer Drug Drug: ✓ + efficacy proven Pre-engagement 15 8

  24. Slide 24: Commercial Infrastructure Established Ahead of FDA Approval

    Oncology · Commercialization Infrastructure Commercial Infrastructure Established Ahead of FDA Approval Commercializationrails — why global pharma keeps choosingLunit Cancer Drug Global Pharma Lunit SCOPE x Test Pathology Labs& CROs Antibody Partners Hospitals / Patients Development Scanners & Chann

  25. Slide 25: 3 Proven Growth Engines, Expanding Markets

    Growth Strategy · Growth Engines 3 Proven Growth Engines, Expanding Markets Cancer Screening INSIGHT · LIL Oncology Lunit SCOPE Medical AI Medical FM · L1 -30B NEW Autonomous AI Autonomous reading All Biomarkers Pan-cancer biomarkers Medical GPT Clinicians · MFDS pending Risk Prediction Breast cance

  26. Slide 26: Thank you

    Thank you Email us at: lunit.io/en/contact More info at: lunit.io/en

  27. Slide 27: Consolidated Financial Statements

    Appendix Consolidated Financial Statements Statement of Financial Position Unit:KRWmillion Income Statement Unit:KRWmillion 2026 2026 2025 2024 2023 2025 2024 2023 3Q 3Q Current Asset 141,842 55,620 111,882 230,418 Operating Income 67,981 83,129 54,180 25,080 Non Current Asset 290,634 314,292 321,03

Lunit — Investor Presentation (November 2026) on 6ix